# Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer

Source: https://onco.cc/trials/nct07214142/  
OnCo record `nct07214142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by The First Affiliated Hospital of University of Science and Technology of China, not yet recruiting.

## Summary

Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer is a phase 2, interventional study registered as NCT07214142 by The First Affiliated Hospital of University of Science and Technology of China, with a registry enrolment figure of 30 participants, started 2025-10-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: PD-1. Conditions listed: Rectal Cancer Patients. Primary outcome: pathological complete response rate. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: TNT-Immunity
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07214142
- Phase: 2
- Setting: Efficacy and Safety of Total Neoadjuvant Chemoradiotherapy Combined With PD-1 Therapy for Locally Advanced Rectal Cancer With High Risk of Recurrence
- Sponsor: The First Affiliated Hospital of University of Science and Technology of China
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07214142: https://clinicaltrials.gov/study/NCT07214142

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07214142.json